Stay updated with breaking news from Pediatric Eoe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Findings from the trial showed that a significantly greater proportion of patients treated with dupilumab met the primary endpoint achieving significant histological disease remission.
The expanded indication makes dupilumab the only approved treatment for eosinophilic esophagitis (EoE) in this age group.
Dupilumab is now indicated for the treatment of eosinophilic esophagitis in children as young as 1 year and weighing at least 15 kg.
Findings from the trial showed that a significantly greater proportion of patients treated with dupilumab met the primary endpoint achieving significant histological disease remission.
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for...